Inclusion criteria
|
(1) Angina pectoris still occurred 3 to 18 months after PCI and was treated and managed according to the Guidelines for Percutaneous Coronary Intervention in China (2016). ?
(2) Patients with stable exertive angina who had ≥2 angina attacks per week in the previous month and whose severity was classified as Canadian Angina severity Scale (CCS) ⅰ - ⅲ were enrolled. ?
(3) Patients with ST segment depression or T wave inversion on electrocardiogram, positive motion plate or ischemic changes assessed by SPECT, PET, MRI, CT and other imaging. ?
(4) Patients who stopped using drugs for activating blood circulation and removing blood stasis for more than 2 weeks. ?
(5) Between 18 and 80 years old, male and female. ?
(6) Voluntarily participate in the study and sign the informed consent.
|
Exclusion criteria:
|
(1) Those eligible for revascularization. ?
(2) Patients with cardiac function grade ⅳ (NYHA scale, see Appendix 2) or CCS Grade ⅳ (Canadian Angina severity Scale). ?
(3) Patients with uncontrolled grade 3 hypertension (systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg), severe cardiopulmonary insufficiency, severe arrhythmia, serious primary diseases of liver, kidney and hematopoietic system, or serious diseases affecting their survival (such as tumor) and mental illness. ?
(4) Combined with other clinical conditions that may increase the risk of bleeding, such as a history of major organ bleeding in the last six months (such as cerebral hemorrhage, upper gastrointestinal bleeding, etc.), platelet count less than 50×10^9/L, abnormal coagulation function, and oral warfarin anticoagulation treatment, etc. ?
(5) abnormal indexes of liver and kidney function (ALT, AST, Scr, BUN 3 times higher than the upper limit of normal reference range). ?
(6) Patients with allergic constitution, or food allergy to multiple drugs, or patients known to be allergic to the study drug (including its ingredients). ?
(7) those who have a pregnancy plan. ?
(8) Breast-feeding women. ?
(9) Vulnerable groups: including neurological diseases, cognitive impairment, critically ill patients, minors, pregnant women, etc. ?
(10) Patients who participated in other clinical trials within the last 1 month. ?
(11) The investigator suggested that there were other patients who were not eligible for inclusion.
|